EBM NEWSDESK ANALYSIS-Anthony Gill
Washington has opened a Section 301 probe into German pharmaceutical pricing — the same legal tool used against China in 2018. Germany’s largest export category to the US is now squarely in the crosshairs, and the timing could hardly be worse for a transatlantic relationship already running on fumes.
The Investigation Opens
US Trade Representative Jamieson Greer initiated a Section 301 investigation against Germany on 18 June, seeking to determine whether what his office calls “persistent underpayment for innovative pharmaceutical products” constitutes an unreasonable or discriminatory trade practice that burdens American commerce. The move follows months of unresolved talks between Washington and Berlin and represents a significant escalation in an already tense transatlantic trade relationship — one that, this year alone, has already absorbed steel tariffs, aluminium tariffs and a running dispute over automotive duties.
“President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development,” Greer said in the announcement. Health Secretary Robert F. Kennedy Jr. added that drug research funding is “a shared burden across wealthy nations.” It’s a genuinely sympathetic argument on paper, and not even a wholly unreasonable one — American patients and insurers do pay markedly more for the same drugs than their German counterparts. The trouble is that Washington has picked a target whose own pricing transparency framework the US government has previously praised as a model. That contradiction is going to be awkward to explain away once this reaches a formal hearing.
Join The European Business Briefing
New subscribers this quarter are entered into a draw to win a Rolex Submariner. Join 40,000+ founders, investors and executives who read EBM every day.
SubscribeWhat Section 301 Actually Does
Section 301 of the Trade Act of 1974 is the same legal mechanism Washington used against China in 2018 to justify tariffs on hundreds of billions of dollars in goods. It allows the USTR to investigate foreign government practices deemed unreasonable, unjustifiable or discriminatory, and — if the investigation finds merit — to impose tariffs or other restrictive measures unilaterally. As one analysis put it, a Section 301 investigation “doesn’t fire tariffs immediately, but it creates the legal framework to do so.” It is, in other words, a loaded gun left sitting on the table during negotiations — and everyone involved knows it.
The process now moves through a structured timeline. Written comment submissions open on 25 June, with a formal public hearing before the Section 301 committee scheduled for September. That sequencing creates an extended window — likely stretching well into autumn — during which the threat of tariffs remains live without yet being imposed, a period of genuine uncertainty for pharmaceutical companies and their investors on both sides of the Atlantic.
The Scale of What’s at Stake
The numbers explain why this matters well beyond a routine bilateral dispute. EU pharmaceutical exports to the US were valued at $127 billion in 2024, making the sector the single largest EU export category to America — larger than automobiles, larger than machinery. If the investigation concludes against Germany and tariffs follow, they could apply to both active pharmaceutical ingredients and finished-dose products crossing the Atlantic in either direction.
The political pressure behind the move has been building for weeks. Just two days before Greer’s announcement, 23 Senate Republicans sent a letter urging action against foreign drug pricing practices generally. Worth noting: that’s a domestic political signal as much as a trade policy one. Drug pricing remains one of the few issues where Republican voters and the administration are genuinely aligned, and Germany has had the misfortune of becoming the most visible test case for that wider grievance.
Why Germany Specifically, and Why Now
The immediate trigger is German domestic policy. Berlin unveiled plans in April for a significant overhaul of its statutory health insurance system, aimed at controlling a widening funding gap in public health spending. The proposed legislation would fast-track additional discounts that pharmaceutical manufacturers must extend to German insurance funds — a cost-containment measure from Berlin’s perspective, and precisely the kind of “fast-tracking” Greer cited as his immediate concern. Several drugmakers have already warned they may delay or withdraw planned product launches in Germany over the pending legislation, even before any US tariff threat materialised. The German Health Ministry did not respond to a request for comment.
There is also a structural irony worth dwelling on, because it genuinely undercuts Washington’s case. Germany’s existing drug pricing arbitration framework already requires manufacturers to submit net pricing data from reference countries — and the White House’s own Council of Economic Advisers has separately cited that exact German structure as the model for designing its own Most-Favoured-Nation drug pricing methodology at home. Washington is, in effect, opening an investigation into a pricing transparency mechanism it has previously held up as best practice. That’s not a fatal flaw in the US case, but it is the kind of inconsistency that German negotiators will be only too happy to point out at the September hearing.
The UK Precedent Washington Wants Germany to Follow
Greer’s statement pointed to a specific template for resolution: the US-UK pharmaceutical pricing arrangement announced on 2 April 2026. Under that deal, the UK agreed to pay higher prices for new medicines through its National Health Service in exchange for a tariff exemption on pharmaceutical exports. “Germany should follow suit with constructive negotiations to address this imbalance,” Greer said, framing tariffs as the consequence of inaction rather than the preferred outcome.
That framing matters for how the dispute is likely to unfold, and it’s worth being honest about what it reveals: the administration would clearly rather extract a pricing concession than actually impose tariffs on a sector this large. Tariffs are leverage here, not the objective. Germany’s negotiators should read that as exactly what it is — a strong opening hand, not a closed door.
The Wider European Risk
The investigation’s significance extends beyond Germany’s own pharmaceutical sector. Escalating trade tensions over drug pricing could plausibly invite retaliatory measures from Brussels, adding a fresh front to a EU-US trade relationship already stretched thin. For European pharmaceutical companies with significant US revenue exposure, the immediate effect is a new layer of uncertainty: a choice, should tariffs materialise, between absorbing the margin hit, passing costs to American customers, or accelerating plans to shift manufacturing onto US soil entirely — exactly the kind of onshoring outcome the Trump administration has pursued explicitly, and successfully, across multiple sectors this year.
For large-cap US pharmaceutical companies, by contrast, a favourable ruling could eventually force higher German — and potentially EU-wide — drug prices, addressing a genuine, long-standing industry grievance. There’s a reasonable argument buried in Washington’s framing here, even if the execution looks heavy-handed: it really isn’t sustainable for one country’s patients to fund the lion’s share of global drug development costs indefinitely. The question is whether a Section 301 investigation is the right tool to fix that, or just the most politically convenient one available right now.
What Happens Next
This is, for now, the opening move in what is likely to be a months-long process. Public comments open in days; the formal hearing isn’t until September; and Greer’s own rhetoric suggests Washington would prefer a negotiated outcome along UK lines over an extended tariff fight. But the broader pattern — this is one of several Section 301 actions the administration has initiated across multiple countries in 2026 — suggests Germany’s case is not an isolated dispute so much as a test of how far the United States can push reference pricing reform across its wealthiest trading partners simultaneously.
My honest read: Germany will negotiate rather than fight this all the way through. The UK already set the precedent, the economic logic of risking $127 billion in exports over a pricing dispute doesn’t hold up, and Berlin has bigger fights to pick with Washington than this one. Expect a quieter resolution than the opening rhetoric suggests — but expect it to take most of the rest of the year to get there.
Related reads:
